Israel - English - Ministry of Health

j-c health care ltd - ustekinumab - concentrate for solution for infusion - ustekinumab 5 mg / 1 ml - ustekinumab - crohn’s disease :stelara is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tnfα antagonist or have medical contraindications to such therapies.ulcerative colitis :stelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies

Israel - English - Ministry of Health

j-c health care ltd - ustekinumab - solution for injection - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - *plaque psoriasisstelara is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to, have a contraindication to, or who are intolerant to other systemic therapies including ciclosporin, methotrexate or psoralen plus u.v (puva) paediatric plaque psoriasisstelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, othersystemic therapies or phototherapies.psoriatic arthritis (psa)stelara, alone or in combination with mtx, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease modifying anti rheumatic drug (dmard) therapy has been inadequatecrohn’s diseasestelara is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tnfα antagonist or have medical contraindications to such therapies.ulcerative colitisstelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies

Israel - English - Ministry of Health

j-c health care ltd - ustekinumab - solution for injection - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - plaque psoriasisstelara is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to, have a contraindication to, or who are intolerant to other systemic therapies including ciclosporin, methotrexate or psoralen plus u.v (puva) paediatric plaque psoriasisstelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, othersystemic therapies or phototherapies.psoriatic arthritis (psa)stelara, alone or in combination with mtx, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease modifying anti rheumatic drug (dmard) therapy has been inadequatecrohn’s diseasestelara is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tnfα antagonist or have medical contraindications to such therapies.ulcerative colitisstelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies

Singapore - English - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - ustekinumab - injection, solution - 45mg/vial - ustekinumab 45mg/vial

Singapore - English - HSA (Health Sciences Authority)

johnson & johnson pte. ltd. - ustekinumab - injection, solution - 90mg/vial - ustekinumab 90mg/vial

Singapore - English - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - ustekinumab - injection, solution - 45mg/0.5ml - ustekinumab 45mg/0.5ml

Singapore - English - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - ustekinumab - injection, solution - 90mg/1ml - ustekinumab 90mg/1ml

European Union - English - EMA (European Medicines Agency)

janssen-cilag international nv - ustekinumab - psoriasis; arthritis, psoriatic; crohn disease; colitis, ulcerative - immunosuppressants - crohn’s diseasestelara is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tnfα antagonist or have medical contraindications to such therapies.ulcerative colitisstelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.plaque psoriasisstelara is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen ultraviolet a.paediatric plaque psoriasisstelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.psoriatic arthritisstelara, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug (dmard) therapy has been inadequate.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - ustekinumab - solution for injection - 90mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - ustekinumab - solution for injection - 90mg/1ml